Completed PHASE2 INTERVENTIONAL 3-arm NCT01176435

Trial of L-DOPA as a Treatment to Improve Vision in Albinism

Clinical Trial to Evaluate Levodopa as Treatment to Improve Vision in Individuals With Albinism

Sponsor: University of Minnesota

Conditions Albinism

Updated 9 times since 2017 Last updated: Apr 30, 2018 Started: Sep 30, 2010 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Albinism and is currently completed. University of Minnesota leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Minnesota

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States